Aun Consulting
2459
Welby
4438
Value Creation
9238
Perseus Proteomics
4882
DMS
9782
JP Stock MarketDetailed Quotes
4506 Sumitomo Pharma
- 722
- +19+2.70%
20min DelayMarket Closed Mar 19 15:30 JST
287.28BMarket Cap-0.91P/E (Static)
731High708Low1.62MVolume708Open703Pre Close1.17BTurnover83852wk High0.95%Turnover Ratio397.90MShares27952wk Low-443.1EPS TTM123.17BFloat Cap4135Historical HighLossP/E (Static)170.59MShs Float279Historical Low-792.79EPS LYR3.27%Amplitude--Dividend TTM1.73P/B100Lot Size--Div YieldTTM
Sumitomo Pharma News
Sumitomo Pharma: Notice of Capital Reorganization within Sumitomo Pharma Group
Sumitomo Pharma: Notice of capital restructuring within our group
Sumitomo Pharma: Statutory ex post facto disclosure documents (company split) (RACTHERA Co., Ltd.)
Sumitomo Pharma: Statutory ex post facto disclosure documents (company split) (S-RACMO Co., Ltd.)
Sumitomo Pharma: Extraordinary Report
Sumitomo Pharma: Conference on Q3 FY2024 (April 1, 2024 to December 31, 2024) Financial Results
Sumitomo Pharma: Notice Concerning Finance Income
Sumitomo Pharma: 2024 (fiscal year ending 2025/3) 3rd quarter Earnings Conference materials
Sumitomo Pharma: Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2025 [IFRS]
Sumitomo Pharma: Notice regarding revisions to earnings forecasts
Sumitomo Pharma: 2024 (fiscal year ending 2025/3) 3rd quarter financial results (IFRS) supplementary materials
Sumitomo Pharma: Supplementary Financial Data (IFRS) for the Third Quarter of the Year Ending March 31, 2025
Sumitomo Pharma: Sumitomo Pharma Announces Revisions to Its Financial Forecasts
Sumitomo Pharma: Notice regarding the recording of financial income (exchange gain)
Sumitomo Pharma: Summary of financial results for the 3rd quarter of the fiscal year ending March 31, 2025 [IFRS] (consolidated)
Sumitomo Pharma: Sumitomo Pharma Announces Agreement on Co-Promotion Collaboration Partner for Marketing of PPLAT XEPLION and XEPLION TRI in Japan
Sumitomo Pharma: Notice of conclusion of an agreement on sales partnership for the long-acting antipsychotics “Zeprion” and “Zeprion TRI” in Japan
Sumitomo Pharma: Legal Advance Disclosure Documents (Company Split) (S-RACMO Co., Ltd.)
Sumitomo Pharma: Legal Advance Disclosure Documents (Company Split) (RACTHERA Co., Ltd.)
Sumitomo Pharma: Interim report.